The primary purpose of FDA's Adverse
Experience Reporting (AER) system is to identify potentially
serious safety problems with licensed biological products, focusing
especially on newly licensed products. Although premarket testing
discloses a general safety profile of a new drug's comparatively
common adverse effects, the larger and more diverse patient
populations exposed to the licensed biological product provides,
for the first time, the opportunity to collect information on rare,
latent, and long-term effects. AER reports are obtained from a
variety of sources, including manufacturers, patients, physicians,
foreign regulatory agencies, and clinical investigators. The
general recordkeeping provisions require manufacturers of licensed
biological products for human use to maintain records of each step
in the manufacture and distribution of products. The recordkeeping
requirements serve preventative and remedial purposes by
establishing accountability and traceability in the manufacture and
distribution of products.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.